Literature DB >> 17943637

Slow progression of HIV-1 infection in a cohort of antiretroviral naïve hotel workers in Dar es Salaam, Tanzania as defined by their CD4 cell slopes.

Muhammad Bakari1, Willy Urassa, Fred Mhalu, Gunnel Biberfeld, Kisali Pallangyo, Eric Sandström.   

Abstract

Data on slow progression following HIV-1 infection in Africa are sparse. From a study on the natural history of HIV-1 infection in Dar es Salaam, Tanzania, an analysis of immunological and clinical data from 237 HIV-1 seropositive individuals was performed. Annual CD4 cell determinations were carried out by flow cytometry. None was on antiretroviral treatment. CD4+ cell slopes were obtained by fitting a linear regression model. A study population of 50 individuals with >3 CD4 cell determinations and followed for >5 y had a mean follow-up of 72.7 months, and mean 5.7 CD4+ cell determinations. With a criterion of maintaining a CD4 cell count >or=500 cells/ml, 8 of the 50 (16.0%) were long-term non-progressors (LTNP). With a definition of maintaining a CD4+ cell slope <or=-10 (a loss of 10 or less cells per y), 13 (26.0%) were long-term slow progressors (LTSP). 11 of them (84.6%) had a baseline CD4 cell count <500 cells/microl and 5(38.5%) had a baseline CD4 cell count less than 350 cells/microl. An analysis of the selection bias introduced during slope determination is presented. With no selection, 24 (23.3%) would have documented slow CD4 progression among those enrolled for 5 or more y regardless of CD4 determinations.

Entities:  

Mesh:

Year:  2008        PMID: 17943637     DOI: 10.1080/00365540701708285

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  6 in total

1.  Effect of improved access to antiretroviral therapy on clinical characteristics of patients enrolled in the HIV care and treatment clinic, at Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania.

Authors:  Sabina F Mugusi; Julius C Mwita; Joel M Francis; Said Aboud; Muhammad Bakari; Eric A Aris; Andrew B Swai; Ferdinand M Mugusi; Kisali Pallangyo; Eric Sandstrom
Journal:  BMC Public Health       Date:  2010-05-28       Impact factor: 3.295

2.  Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.

Authors:  Thierry Buclin; Amalio Telenti; Rafael Perera; Chantal Csajka; Hansjakob Furrer; Jeffrey K Aronson; Paul P Glasziou
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

3.  HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study.

Authors:  Michael Odida; Sven Sandin; Florence Mirembe; Bernhard Kleter; Wim Quint; Elisabete Weiderpass
Journal:  Infect Agent Cancer       Date:  2011-06-25       Impact factor: 2.965

4.  Previously Unidentified Single Nucleotide Polymorphisms in HIV/AIDS Cases Associate with Clinical Parameters and Disease Progression.

Authors:  Vladimir V Anokhin; Liliia B Bakhteeva; Gulshat R Khasanova; Svetlana F Khaiboullina; Ekaterina V Martynova; Richard L Tillett; Karen A Schlauch; Vincent C Lombardi; Albert A Rizvanov
Journal:  Biomed Res Int       Date:  2016-12-05       Impact factor: 3.411

5.  Association of interleukin-27 gene polymorphisms with susceptibility to HIV infection and disease progression.

Authors:  Xiao-Xia Pang; Shun-Da Luo; Ting Zhang; Feng Shi; Chun-Fang Wang; Xing-Hong Chen; Yu-Xia Wei; Li Qin; Jing-Xi Wei; Xiao-Qiong Luo; Jun-Li Wang
Journal:  J Cell Mol Med       Date:  2019-01-10       Impact factor: 5.310

6.  Mathematical Model Impact Analysis of a Real-Life Pre-exposure Prophylaxis and Treatment-As-Prevention Study Among Female Sex Workers in Cotonou, Benin.

Authors:  Lily Geidelberg; Kate M Mitchell; Michel Alary; Aminata Mboup; Luc Béhanzin; Fernand Guédou; Nassirou Geraldo; Ella Goma-Matsétsé; Katia Giguère; Marlène Aza-Gnandji; Léon Kessou; Mamadou Diallo; René K Kêkê; Moussa Bachabi; Kania Dramane; Christian Lafrance; Dissou Affolabi; Souleymane Diabaté; Marie-Pierre Gagnon; Djimon M Zannou; Flore Gangbo; Romain Silhol; Fiona Cianci; Peter Vickerman; Marie-Claude Boily
Journal:  J Acquir Immune Defic Syndr       Date:  2021-02-01       Impact factor: 3.771

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.